See more : Action Energy Inc. (AECFF) Income Statement Analysis – Financial Results
Complete financial analysis of Aileron Therapeutics, Inc. (ALRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aileron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The CannaBusiness Group, Inc. (CBGI) Income Statement Analysis – Financial Results
- Hengdian Group Tospo Lighting Co., Ltd. (603303.SS) Income Statement Analysis – Financial Results
- Cyclo Therapeutics, Inc. (CYTH) Income Statement Analysis – Financial Results
- Fujitsu Limited (FJTSY) Income Statement Analysis – Financial Results
- Pires Investments plc (PIRI.L) Income Statement Analysis – Financial Results
Aileron Therapeutics, Inc. (ALRN)
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.35M |
| Cost of Revenue | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 9.33M | 12.23M |
| Gross Profit | -119.00K | -169.00K | -121.00K | -163.00K | -155.00K | -218.00K | -95.00K | -232.00K | -325.00K | -9.33M | 10.12M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45.29% |
| Research & Development | 3.99M | 17.97M | 17.01M | 11.17M | 17.66M | 18.45M | 14.24M | 10.28M | 7.83M | 9.33M | 12.23M |
| General & Administrative | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Other Expenses | 928.00K | 318.00K | 441.00K | -800.00K | 0.00 | 0.00 | 0.00 | -18.17M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 6.70M | 6.84M |
| Cost & Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 16.03M | 19.07M |
| Interest Income | 0.00 | 0.00 | 0.00 | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 585.00K | 774.00K |
| EBITDA | -15.61M | -27.48M | -26.48M | -20.33M | -29.80M | -31.33M | -23.01M | -17.94M | -12.57M | -15.44M | 4.06M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18.16% |
| Operating Income | -16.28M | -27.65M | -26.61M | -20.50M | -29.96M | -31.90M | -23.01M | -18.17M | -12.89M | -16.03M | 3.28M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.69% |
| Total Other Income/Expenses | 544.00K | 318.00K | 441.00K | -661.00K | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K |
| Income Before Tax | -15.73M | -27.33M | -26.21M | -21.16M | -29.37M | -31.55M | -22.60M | -18.12M | -12.88M | -16.02M | 3.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.72% |
| Income Tax Expense | 0.00 | -318.00K | -441.00K | 661.00K | -587.00K | 355.00K | 34.00K | 0.00 | 0.00 | 43.00K | 3.10M |
| Net Income | -15.73M | -27.01M | -25.76M | -21.82M | -28.78M | -31.55M | -22.60M | -18.12M | -12.88M | -16.07M | 194.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.87% |
| EPS | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -845.63 | 10.21 |
| EPS Diluted | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -844.96 | 10.85 |
| Weighted Avg Shares Out | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.00K | 19.00K |
| Weighted Avg Shares Out (Dil) | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.02K | 17.89K |
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian...
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for...
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for...
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024
Aileron Therapeutics Announces CEO Transition
Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases WALTHAM, Mass.
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Topline results from Phase 1b study of LTI-03, Aileron's novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 Topline results from Phase 1b study of LTI-03, Aileron's novel Caveolin-1-related peptide...
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Panel discussion will highlight LTI-03, Aileron's novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis Panel discussion will highlight LTI-03, Aileron's novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF) Financing proceeds of approximately $18 million from a private placement anticipated to fund completion of the ongoing Phase...
Source: https://incomestatements.info
Category: Stock Reports